

The Canadian Association for Population Therapeutics/
Association Canadienne pour la Thérapeutiques des Populations

Presents:

"Reimagining our Canadian Potential: Working Together through Partnerships and Collaborations"

PROGRAM

October 23rd– 24th, 2023 MaRS Discovery District 101 College Street Toronto, Ontario

CAPT-ACTP MISSION & VISION

The CAPT-ACTP Mission is to advance epidemiologic research of therapeutic and other health interventions in Canada by:

- Bringing together diverse perspectives in a neutral forum
- Facilitating open exchange of ideas and collaboration
- Influencing policy and practice

The CAPT-ACTP Vision is to become the recognized Canadian leader for linking population-based therapeutic research, policy and practice that may lead to improved health outcomes.

www.capt-actp.ca

CAPT-ACTP 2023 Conference Committees

Executive:

President – Shanna Trenaman President Elect – Julia Shen Past President – Mina Tadrous Treasurer – Lois Mitchell

Finance Committee:

Treasurer – Lois Mitchell Administrator – Peggy Kee

Local Organizing Committee:

Members – Peggy Kee

Yen Nguyen Joan Paulin

Marketing, Membership & Student Committee:

Chair— Shanna Trenaman

Student Rep – Wajd Alkabbani (student rep)

Members – Jason R. Guertin

Tim Marshall
Dan Moldaver
Peggy Kee

Partnership Committee:

Chair – Mina Tadrous

Members – Alexandra Chambers

Shazia Hassan Adam Haynes Lois Mitchell Raina Rogoza Julia Shen Belinda Yap Peggy Kee

Scientific Committee:

Co-Chairs – Julia Shen & Shanna Trenaman Members – Wajd Alkabbani (student rep)

Alexandra Chambers
Jason R. Guertin
Shazia Hassan
Adam Haynes
Tim Marshall
Dan Moldaver
Yen Nguyen
Joan Paulin
Raina Rogoza
Mina Tadrous
Belinda Yap

Message from the President

We extend a warm welcome to everyone joining us at the 2023 Canadian Association for Population Therapeutics (CAPT) / Association Canadienne pour la Thérapeutique des Populations (ACTP) annual conference. It does not matter if you are joining for your 1st or 14th CAPT / ACTP meeting we are excited to connect and reflect on the issues facing those of us engaged in population therapeutics, real-world evidence, and health technology assessment in Canada. CAPT / ACTP recognizes the diverse nature of the work of those involved in population therapeutics in Canada and this year we have focused our program on "Reimagining our Canadian Potential: Working Together Through Partnerships and Collaborations."

Healthcare in Canada is facing substantial stress. There is lots of work needing to be done, there are changes in the healthcare workforce composition, there has been redeployment of healthcare funding as we try to recover from the last 3 years' disruption, and these are just a few of the challenges healthcare in Canada is facing. We at CAPT / ACTP believe that learning from each other is likely the best way for us to find success. We look forward to hearing about how working together can benefit all Canadians.

I would like to thank all our partners at all levels of sponsorship for their support. Your commitment to CAPT / ACTP is crucial for us to hold our annual conference and continue these meaningful conversations. We also are pleased to recognize and welcome the invited speakers, moderators, and poster presenters who are going to share their expertise with us.

This event would not be possible without the work of our CAPT / ACTP board and committees. I would like to recognize the Scientific Planning Committee who have built the program, the Partnership Committee that have liaised with our partners, the Membership Marketing and Students Committee who have focused on our students' experience, and the local organizing committee who have made it all happen.

Please enjoy your time at the CAPT / ACTP annual conference. Follow us on Twitter (@CAPT_ACTP), join our group on LinkedIn, and mention the conference with the hashtag #CAPT_ACTP2023. We are looking forward to the event.

Shanna Trenaman CAPT / ACTP President

Conference Overview

Welcome to the 2023 CAPT-ACTP conference, we are so grateful to see everyone in person again! The theme of this year's conference, "Reimagining our Canadian Potential: Working Together through Partnerships and Collaborations" aims to be thought provoking and solutions oriented as we move to explore solutions in the healthcare space in a post-pandemic era. Due to Canada's vast geographical area and complex systems, there often exists silos in decision-making, communication, and policy creation. It will be fitting to bring stakeholders together to explore ways of working to simplify processes and improve the well-being of Canadians.

Over the last year, the Scientific Program Committee, our Partners, and invited Speakers have been meticulously preparing for the conference. We are pleased to have an incredible keynote address for this year, presented by Ivy Bourgeault, exploring the current state of the Canadian Healthcare Workforce. Our panel sessions this year will explore health policies within Canada and how collaboration among stakeholders can strengthen these policies and improve access in a meaningful manner. The panels will also explore the continuum of research happening in Canada and beyond in population-based therapeutics, policy, epidemiology, and practice. We are pleased to offer a poster session as well as a career fair as part of the conference programming and we hope attendees have the opportunity to visit these offerings.

The Scientific Program Committee would like to thank our partners who have made the presentation of this year's conference possible and have continued to support and collaborate with CAPT-ACTP. We have a great agenda lined up for this year's conference and we hope everyone takes the opportunity to engage, have meaningful discussions, learn, and network. We hope everyone has a CAPTivating experience during this year's conference!

Julia Shen & Shanna Trenaman CAPT-ACTP Scientific Program Committee Co-Chairs

We are pleased to present a pre-conference event

National Town Hall on RWE: Update on ongoing Canadian Initiatives

Sunday October 22nd, 2023

1:00PM - 4:30PM

Leslie Dan Faculty of Pharmacy - University of Toronto (144 College St.)

IN-PERSON

Description: The intent of this half-day town hall is to gather stakeholders in the real world evidence (RWE) space together to share and communicate ideas and updates regarding ongoing work in Canada and across the world. In addition to Canadian experts, we will include international speakers to share their experiences and work. Specifically, this town hall will provide an opportunity for stakeholders to present updates and share their current RWE

12:30PM – 1:00PM	Agenda Registration
1:00PM - 1:30PM	RWE Update CADTH Nicole Mittmann, PhD, Chief Scientist and Vice President, Scientific Evidence, Methodologies and Resources. Farah Husein, Director, Science & Methods - Evidence Standards
1:30PM - 2:30PM	Global Perspective - RWE and Data Linkage Dr. Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology NIHR Senior Research Fellow, CSM-NDORMS, University of Oxford
2:30PM - 3:30PM	Town Hall Style Event Julie Patenaude, Director, PeriPharm Ross Wallace, Principal, Santis Health Graham Statt, I2U's Ad Board member Jeff Round, IHE Allison Wills, 20Sense Corp
3:30PM - 4:30PM	RWE Networking

initiatives. Registration

https://www.capt-actp.ca/register/

\$50.00 + HST Combined with registration to CAPT 2023 Conference (Oct 23 & 24) \$150.00 + HST RWE workshop only

Students & Patients interested in attending please contact <u>CAPT Administration</u> for *complimentary* registration

Monday, October 23, 2023

7:00AM – 8:30AM Registration / Breakfast

Location: Lower Concourse Auditorium Foyer

8:30AM – 8:45AM Welcome to Day 1

Location: Lower Concourse Auditorium

Speaker: Shanna Trenaman, CAPT-ACTP President

8:45AM – 9:30AM Keynote Address:

Speaker: Ivy Bourgeault

Title: The urgent need to address health worker retention and

how

Session Overview:

9:30AM –10:30AM Session 1 (Sponsored by Roche)

Title: From Guidance to real-world application: How can we

continue to better use RWD in HTA decision-making?

Moderator: Justin Mallet, Roche Canada

Speakers: Laurie Lambert, Special Projects Advisor, CADTH

Anne Forsyth, Manager, Data Standards, CIHI Victoria Hodgkinson, Executive Director, Canadian Neuromuscular Disease Registry and Chief Scientific

Officer, Lumiio Inc

Session Overview: In a context where health technologies are increasingly complex and budgets constrained, RWD has the potential to reduce uncertainty and increase confidence in HTA and regulatory decision-making. However, the use of RWD raises challenges for decision-makers: varying quality, lack of standards, potential biases, etc. The community seeks more guidance on how to navigate between robustness and quantity of RWD to support decision-making, but the variety of cases where it can be useful and maturity levels of RWD make it hard to avoid coming up with broad principles. How can public and private stakeholders continue to collaborate to establish appropriate practices in using RWD to bring the right innovative solutions to the right patients at the right time efficiently.

10:30AM - 11:00AM Break

11:00AM – 12:00PM Session 2 (Sponsored by Pfizer)

Title: Drug shortages and supply: perspectives from Canada

and beyond on the impact, challenges and proposals

for future collaboration

Moderator: Mina Tadrous, Assistant Professor, University of Toronto Speakers: Stephanie Di Trapani, Director, Drug Shortages Division at

Usella Canada

Health Canada

Christine Donaldson, Interim President and CEO of

HealthPRO Canada

Session Overview: We are all aligned that no one wants to experience a drug shortage. This panel will focus on the diverse perspectives of individuals and organizations who want to work better together to manage the various aspects of drug supply and shortages that have the potential to affect many Canadians. The scope of the problem and the impact on various stakeholders will be discussed alongside policy matters and potential solutions. Woven throughout the panel discussion will be the aspects of collaboration and conversations that need to happen today and regularly, and we hope to demonstrate why having national initiatives that bring in perspectives from across the country as well as that of international organizations are of benefit to us all.

12:00PM - 1:00PM Lunch

Location: Lower Concourse Auditorium Foyer

1:00PM – 2:00PM Session 3 (Sponsored by Apellis)

Title: Prioritizing eye health for Canadians and system

readiness

Moderator: Larissa Moniz, PhD – Director of Research and Mission

Programs @ Fighting Blindness Canada

Speakers: The Honourable Judy Sgro, PC, MP, Humber River–Black

Creek, Ontario

Dr. Nirojini Sivachandran - Vitreoretinal Surgeon - Toronto

Retina Institute

Dr. Keith Gordon, Senior Research Officer, Canadian

Council of the Blind

Session Overview: This session will seek to increase awareness & the importance of prioritizing vision health. There is an expected "Rising Tide" of retinal conditions that will require significant planning. This session will review a typical patient journey for a person who experiences a retinal disease and the various challenges along the way. We will highlight challenges with introducing innovation in the space of ophthalmology, focusing on expected and existing system constraints, issues with existing procedures, and practices to optimize eye health and infrastructure required to integrate new treatments.

2:00PM – 3:00PM Session 4 (Sponsored by Merck)

Title: How value-based healthcare can be applied to improve

evaluation and funding decisions in rare diseases and cancer, drawing on global examples and emerging

best practices in Canada

Moderator: Bill Dempster, CEO, 3Sixty Public Affairs

Speakers: Eva Villalba, Executive Director, Quebec Cancer Coalition

and Founding Partner, Expertise Value in Health Joan Paulin, Pulmonary Hypertension Association of

Canada Board Member and Ambassador

Fred Horne, Senior Fellow, CD Howe Institute and Senior

Advisor, 3Sixty Public Affairs

Zayna Khayat, in-house health futurist with Deloitte

Canada's Healthcare practice

Session Overview: In recent years, Value-Based Healthcare (VBHC) has become a dominant framework for the development of strategies to improve patient and health system outcomes. While value-based initiatives are often thought of as mechanisms to support improvements to existing models of care delivery associated with a specific disease or condition, VBHC principles, and methodology can and should also be applied to improve policy, evaluation, and funding decisions. This panel will explore the potential for value-based approaches to support early and better access to innovative therapies for the increasing number of Canadians living with cancer and rare diseases. Participants will have the opportunity to hear about and discuss:

- Underlying principles and tools that can support a value-based vs. cost-based approach to decision-making in the evaluation and reimbursement of innovative therapies;
- Challenges and opportunities to decision-making focused on value across the full continuum of prevention and care (vs. clinical outcomes only);
- Current VBHC initiatives in Quebec cancer care and other best practices that demonstrate the ability of VBHC approaches to measurably improve outcomes that matter to patients;
- New approaches to collaboration required to achieve success in VBHC, including the central role of patients and patient organizations and opportunities for governments and other stakeholders to adapt or replace legacy processes;
- Take-home ideas and resources for participants to promote action in VBHC within their organizations.

3:00PM - 3:30PM Break

3:30PM – 4:30PM Session 5 (sponsored by Eisai)

Title: Supporting innovative therapeutics for dementia

treatment and beyond

Moderator: Cathy Barrick, CEO, Alzheimer Society of Ontario Speakers: Jennifer Ingram, MD, FRCPC, DSc (Hons), Internal and

Geriatric Medicine; Founder, Kawartha Centre

Adam Morrison, Director, Policy and Planning, Provincial

Geriatrics Leadership Ontario

Jessica Bindra, Caregiver of a Person Living with

Dementia; Director, Privacy, Quality and Client Risk and

Safety, Alzheimer Society of Ontario

Session Overview: We are at the edge of a new treatment paradigm for dementia patients focused on modifying the disease itself. Novel anti-amyloid therapies were recently approved by the FDA and are in various stages of review by Health Canada. While a source of optimism, healthcare systems in Canada are stretched and under-equipped to care for those living with dementia, leading to a tremendous burden on caregivers. These new treatment options will require earlier screening and diagnosis of appropriate patients, additional treatment administration needs, and monitoring for adverse events. Without appropriate preparations, this will lead to increased pressures on health systems exposing (and possibly exacerbating) the weaknesses and gaps that already exist. Reorganization of care and reallocation of existing resources will be needed to prepare for and deliver improved care for older adults living with dementia. This session will provide attendees with various perspectives from the Alzheimer's Society, those living with dementia, clinicians, administrators, and government on how we make progress in treating dementia and capture the full value from these upcoming resource intensive new treatments.

4:30PM – 5:30PM Oral Presentations of top-ranked research abstracts

Moderator: Julia Shen, CAPT-ACTP President Elect

Mark Connolly

Fiscal Cost-Benefit Analysis of Antiretroviral Therapy for the Management and Prevention of Human Immunodeficiency Virus (HIV) in Canada 1987-2021

Naomi Chouinard

Comparing approaches to determine the costs of treating burn victims in Quebec

Marina Birck

Extended-release prescription opioids and risk of HCV infection among people who inject drugs: Findings from the HEPCO cohort in Montreal, Quebec, Canada

Shenthuraan Tharmarajah

Changes in Diclectin Utilization Trends in Ontario Following Media Attention: A Time-Series Analysis

5:30PM - 5:45PM Day 1 Summary

Speaker: Shanna Trenaman, CAPT-ACTP President

5:45PM – 6:30PM Poster Presentation Session (Sponsors:

Location: Upper Level

Drinks and Hors D'oeuvres

Location: Lower Concourse Auditorium Foyer

Tuesday, October 24, 2023

7:30AM – 8:45AM Registration / Breakfast

Location: Lower Concourse Auditorium Foyer

8:00AM – 9:00AM Early Morning Workshop

Title: Propensity Scores – From lingo to applications in real

world evidence

Location: Lower Concourse Auditorium

Speaker: Mina Tadrous, Assistant Professor, University of Toronto

Jason R. Guertin, Associate Professor, Université Laval

Session Overview: Propensity score (PS) methods are a group of methods that are commonly used to adjust for confounding within observational and real-world evidence studies. This workshop will introduce attendees to basic concepts related to confounding and the various PS methods. In addition, the speakers will highlight some limits and inappropriate use of PS and suggest alternatives attendees could consider within their own work

9:00AM – 4:30PM Career Fair / Partner Displays

Location: Lower Concourse Auditorium Foyer Participants: AstraZeneca, IQVIA, Eversana, Roche,

University of Toronto

9:00AM - 9:15AM Welcome to Day 2

Location: Lower Concourse Auditorium

Speaker: Shanna Trenaman, CAPT-ACTP President

9:15AM - 10:15AM Session 6 (Sponsored by IQVIA)

Title: Rare Disease Strategy – Evolution, Needs and Future

Steps

Moderator: Brad Millson, IQVIA Canada

Speakers: Don Husereau, Adjunct Professor of Medicine, University

of Ottawa

Dr. Kevin Kuo, Hematologist and Associate Professor,

University of Toronto

Daniel MacDonald, Director General, Office of

Pharmaceuticals Management Strategies and Drugs for Rare Diseases, Strategic Policy Branch, Health Canada Bob McLay, General Manager Canada, Sobi and Chair of

RAREi

Durhane Wong-Rieger, President & CEO, Canadian

Organization for Rare Disorders (CORD)

Session Overview: This panel will convene a group of experienced and expert thinkers on the current landscape and strategies for the treatment of rare diseases. We will discuss several important areas of interest and related questions:

- 1. HTA decision making for DRDs Should a DRD-specific HTA process be considered in Canada that ideally leverages results of improved evidence generation based on pan-Canadian DRD/rare disease data infrastructure?
- 2. Pathways for timely access to DRDs What are the alternatives to managed access pathways?
- 3. Healthcare system readiness Are key elements of the healthcare system (e.g., diagnostic infrastructure and funding for tests, access to drugs, knowledge, and expertise) currently lacking to ensure timely therapy for patients with rare diseases?

The main objective of the session is to discuss answers to the posed questions and outline possible action items for key stakeholders.

10:15AM - 10:45AM Break

10:45AM – 11:45AM Session 7 (Sponsored by AbbVie)

Title: Exploring diverse approaches to health technology

assessment and reimbursement for cancer therapies: Can new Canadian collaborations help enable timely

access?

Moderator: Allison Wills. 20Sense

Speakers: Sudha Kutty, Executive Vice President, Evidence,

Products and Services, CADTH

Christina Sit, The Leukemia & Lymphoma Society Dr. Joanna Gotfrit, The Ottawa Hospital Cancer Centre Tara Cowling, Medlior Health Outcomes Research

Session Overview: This session will explore how international jurisdictions have employed collaborative health technology assessment approaches to enable timely access to oncology therapies, with a focus on the opportunity to use such approaches for Canada. The panel will then discuss CADTH's proposed time-limited recommendation process and hear from patient and physician communities on how new Canadian collaborations can support timely access for patients to oncology therapies.

11:45AM - 1:00PM Lunch

Annual General Meeting & Awards Presentations

Location: Lower Concourse Auditorium

Speaker: Shanna Trenaman on behalf of the CAPT-ACTP Board

1:00PM - 2:00PM Session 8 (Sponsored by Innovative Medicines Canada)

Title: Public payer best practices for providing timely patient

access to cancer therapies

Moderator: Dr. Judith Glennie – President, J.L. Glennie Consulting Inc.

Speakers: Kathy Gesy, Oncology Consultant

Yen Nguyen, Pharmacist, Pharmacoeconomist & Ex-payer Dr. Joanna Gotfrit, The Ottawa Hospital Cancer Centre Christina Sit, The Leukemia & Lymphoma Society Scott Gavura, Director, Provincial Drug Reimbursement

Programs, Ontario Health

Session Overview: To discuss recent research on time to listing of oncology medications as well as best practices in their integration into the Canadian cancer system. The perspectives of patients, clinicians, and policymakers will be explored.

2:00PM - 2:30PM Award Ceremony - Closing Remarks

Location: Lower Concourse Auditorium

Speaker: Julia Shen, CAPT-ACTP President 2024

For any inquiries (abstracts, hotel, registration, etc.), please contact Ms. Peggy Kee (peggy.kee@sunnybrook.ca), or visit the CAPT-ACTP website at: (www.capt-actp.ca).

We gratefully acknowledge sponsorship of the 2023 CAPT-ACTP conference by the following donors:

2023 Conference Partners

Platinum

AbbVie, Apellis, Eisai, Hoffmann-La-Roche, IMC, IQVIA, Merck, Pfizer

<u>Gold</u>

AstraZeneca, Eversana

Silver

Amgen, Bayer, Innomar Strategies, Novartis, PDCI/McKesson

Bronze

Astellas, CADTH, CSL Behring, HOPE Research Centre, Sanofi

PLATINUM

















GOLD





SILVER











BRONZE







